Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML - Seite 2

“The main reason AML is so hard to treat is a small population of therapy-resistant leukemia stem cells, which drives the relapse of the disease after initial successful treatment. Novel therapies will have to aim at targeting and eliminating these treatment-resistant LSCs,” said Professor Ochsenbein. “We are excited to join forces with Molecular Partners to work to evaluate this novel therapeutic option. Hopefully, emerging therapeutics like MP0533 will be able to provide a much-needed solution for AML patients.”

About Molecular Partners’ acute myeloid leukemia (AML) program
Molecular Partners’ T-cell engager (TCE) programs leverage the cell surface protein CD3 as a powerful immune activator, complemented by novel control mechanisms designed to help direct CD3-mediated cytotoxicity with heightened precision. Molecular Partners first TCE candidate is being developed as a unique multi-specific treatment for AML. Its component DARPin modules are designed to deliver a deeper attack on a broader range of highly variable tumor cells while lowering the risk to healthy cells. This may allow Molecular Partners to significantly shift the therapeutic window for TCE use in AML and potentially avoid the trade-off between effective dosage and safety that other therapeutic developers have had to make.

About Molecular Partners’ Immuno-oncology Product Candidates
Molecular Partners is developing several candidates designed to activate the immune system to fight cancer while reducing damage to healthy cells. These candidates use multiple novel DARPin technologies potentially applicable against a wide range of tumor types, including DARPin candidates with the ability to restrict immune activation to the tumor microenvironment, the ability to target intracellular disease-associated proteins, and multiple novel control mechanisms for immune activation designed to direct immune attack to the right cells, at the right place, and at the right time. These capabilities can be combined during candidate design through the inherent modularity of the DARPin platform, to provide precise control over immune activation and potentially enable more effective cancer immunotherapies.